Pharmaceuticals Ltd.


Preventerm (patent pending) blocks 3 out of the 5 factors that prepare the cervix for labor, representing an extremely effective multi-step inhibition of the enzymes that begin the labor process

Attacking metalloproteinases and cytokine precursors, Preventerm interrupts several steps in the biological pathway thereby preventing labor for an unprecedented length of time – up to a week, and with 90% efficacy

Inducterm (patent issued) works by the reverse process, providing collagenase to begin the breakdown of cervix proteins and thereby inducing labor in a matter of 3-5 hours

Both drugs are based on already scientifically and clinically proven molecules that are safe, inexpensive, and easily administered with minor to no side effects


Various scientific case reports on the use of the Preventerm source molecule report no adverse side effects to the mother or infant

Initial tests of Preventerm have shown a 90% efficacy rate in preventing preterm labor – overwhelmingly more effective than any of the currently available treatment modalities

Preventerm stands to decrease the overall expense of preterm infant health care and will reduce infant mortality as well as post-natal complications considerably

We intend to generate revenue through joint and/or strategic collaborations with large pharmaceutical and biotechnology companies in order to further develop our products, jointly facilitate regulatory approval, and subsequently to bring our products to the global markets

A unique investment opportunity: Patented and patent-pending breakthrough drugs Direct solution to a pressing market need Vast expertise in the OB/Gyn industry Several discrete multi-billion dollar markets Strategic value to large pharmaceutical companies